Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;36(4):948-954.
doi: 10.1002/mds.28406. Epub 2020 Nov 30.

Is Levodopa Response a Valid Indicator of Parkinson's Disease?

W R Wayne Martin  1 , Michael Miles  2 , Qiaonan Zhong  3 , Johanna Hartlein  2 , Brad A Racette  2   4 , Scott A Norris  2   5 , Mwiza Ushe  2 , Baijayanta Maiti  2 , Susan Criswell  2 , Albert A Davis  2 , Paul T Kotzbauer  2 , Nigel J Cairns  6 , Richard J Perrin  2   7 , Joel S Perlmutter  2   5   8
Affiliations

Is Levodopa Response a Valid Indicator of Parkinson's Disease?

W R Wayne Martin et al. Mov Disord. 2021 Apr.

Abstract

Background: The clinical diagnosis of Parkinson's disease (PD) requires the presence of parkinsonism and supportive criteria that include a clear and dramatic beneficial response to dopaminergic therapy. Our aim was to test the diagnostic criterion of dopaminergic response by evaluating its association with pathologically confirmed diagnoses in a large population of parkinsonian patients.

Methods: We reviewed clinical data maintained in an electronic medical record from all patients with autopsy data who had been seen in the Movement Disorders Center at Washington University, St. Louis, between 1996 and 2018. All patients with parkinsonism who underwent postmortem neuropathologic examination were included in this analysis.

Results: There were 257 unique parkinsonian patients with autopsy-based diagnoses who had received dopaminergic therapy. Marked or moderate response to dopaminergic therapy occurred in 91.2% (166/182) of those with autopsy-confirmed PD, 52.0% (13/25) of those with autopsy-confirmed multiple systems atrophy, 44.4% (8/18) of those with autopsy-confirmed progressive supranuclear palsy, and 1 (1/8) with autopsy-confirmed corticobasal degeneration. Other diagnoses were responsible for the remaining 24 individuals, 9 of whom had a moderate response to dopaminergic therapy.

Conclusion: A substantial response to dopaminergic therapy is frequent but not universal in PD. An absent response does not exclude PD. In other neurodegenerative disorders associated with parkinsonism, a prominent response may also be evident, but this occurs less frequently than in PD. © 2020 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; diagnostic specificity; levodopa; parkinsonism.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none

References

    1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30: 1591–601. - PubMed
    1. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993; 50: 140–148. - PubMed
    1. Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998; 55: 957–961. - PubMed
    1. O’Sullivan SS, Massey LA, Williams DR et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008; 131: 1362–1372. - PubMed
    1. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3: 93–103. - PubMed

Publication types

Grants and funding